<scp>Nuclear Magnetic Resonance</scp> ‐based fragment screen of the <scp>E3</scp> ligase Fem‐1 homolog B

Targeted protein degradation using PROTACs (PROteolysis TArgeting Chimeras) has emerged as a transformative therapeutic strategy, largely relying on a small number of E3 ubiquitin ligases such as CRBN and VHL. However, resistance, toxicity, and poor oral bioavailability limit the utility of PROTACs and highlight the need to expand the E3 ligase toolbox. Fem-1 homolog B (FEM1B) is a lesser-known E3 ligase that offers a promising alternative due to its broad expression and ability to recognize diverse degron motifs. Here, we describe the development of a stable construct of FEM1B, the results of a protein-observed NMR-based fragment screen using this construct, and the X-ray structures of some of the fragment hits when bound to the protein. From these results, new PROTACs utilizing FEM1B as the E3 ligase may be discovered, providing an alternative E3 ligase for targeted protein degradation.

Authors

Institutions

Publication Details

Journal
Protein Science
Published
2025-11-13
DOI
https://doi.org/10.1002/pro.70365
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nuclear Magnetic Resonance ‐based fragment screen of the E3 ligase Fem‐1 homolog B

Kangsa Amporndanai, Kristie L. Rose, Alex G. Waterson, Stephen W. Fesik et al.
Protein Science
Protein Degradation and Inhibitors
article

Nuclear Magnetic Resonance ‐based fragment screen of the E3 ligase Fem‐1 homolog B

Kangsa Amporndanai, Kristie L. Rose, Alex G. Waterson, Stephen W. Fesik, Ashley J. Taylor, Jade M. Katinas, Roberto A. Crespo, Peter C. Gareiss, Jason Phan
article en

Abstract

Targeted protein degradation using PROTACs (PROteolysis TArgeting Chimeras) has emerged as a transformative therapeutic strategy, largely relying on a small number of E3 ubiquitin ligases such as CRBN and VHL. However, resistance, toxicity, and poor oral bioavailability limit the utility of PROTACs and highlight the need to expand the E3 ligase toolbox. Fem-1 homolog B (FEM1B) is a lesser-known E3 ligase that offers a promising alternative due to its broad expression and ability to recognize diverse degron motifs. Here, we describe the development of a stable construct of FEM1B, the results of a protein-observed NMR-based fragment screen using this construct, and the X-ray structures of some of the fragment hits when bound to the protein. From these results, new PROTACs utilizing FEM1B as the E3 ligase may be discovered, providing an alternative E3 ligase for targeted protein degradation.

Protein ScienceVol. 34(12)
Vanderbilt University (US), Arvinas (United States) (US)
National Science Foundation, U.S. Department of Energy, Vanderbilt University, National Institutes of Health, Office of Science, University of California, San Francisco, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Openalex Percentile: Top 70%
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

<scp>Nuclear Magnetic Resonance</scp> ‐based fragment screen of the <scp>E3</scp> ligase Fem‐1 homolog B — Kangsa Amporndanai, Kristie L. Rose, et al. · Protein Science (2025) | TGRS Research Map | TGRS